🧬 Can triplet combinations improve outcomes in advanced urothelial cancer? And how do we manage their toxicity? #OAOnTheGo Series

In this new OncoAlert video live from the floor at #ESMO26, Dr. Sara Coca Membribes, @scocmem medical oncologist and genitourinary (GU) clinical research fellow at the Barts Cancer Institute🇬🇧 , discusses the results of TROPHY Cohort 7, evaluating sacituzumab govitecan (SG), enfortumab vedotin (EV), and a PD-1 inhibitor.

🔬 Key takeaways:
▪️ All 18 patients achieved tumor shrinkage, with durable responses.
▪️ No treatment-related deaths were reported.
▪️ Approximately 60% of patients experienced Grade 3 adverse events.
▪️ G-CSF support was mandatory in the study.

With several trials exploring frontline triplet combinations using different ADCs, payloads, and targeted therapies—including FGFR3 inhibition in the FORAGER trial—the challenge is not only achieving efficacy, but also managing toxicity without compromising treatment outcomes.

🎥 Watch Dr. Sara Coca Membribes' video for her insights into these promising strategies and why toxicity management is essential for the future of combination therapy.

#UrothelialCancer #BladderCancer

Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3